CareCulture Health Partners

Belkins
CareCulture Health Partners is a privately-owned emergency, hospital medicine, and urgent care management services company headquartered in Dallas, Texas. We transform emergency department, urgent care, and hospitalist teams into high-functioning, clinician-driven groups by empowering clinicians, aligning with your facility's goals, and establishing a culture of accountability and lateral service. We offer administrative, clinical, and operational management services that transform and improve emergency departments, urgent care centers, and hospitalist programs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDTECH

GP-WRITE PARTNERS WITH DNA SCRIPT TO ACCELERATE DNA-WRITING TECHNOLOGY AND ACCESSIBILITY

Genome Project-write | October 18, 2021

news image

GP-write’s CAD is a one-stop shop for microbe, plant and animal genome writing and redesign. Its automated workflow allows users to rapidly upload a genome, redesign it and synthesize the new sequence. The tool enables researchers to directly order synthetic DNA or related products and services from GP-write’s affiliated members. DNA Script’s SYNTAX System, a benchtop DNA printer powered by their groundbreaking enzymatic DNA synthesis (EDS) technology, enables us...

Read More

CELL AND GENE THERAPY

TAYSHA GENE THERAPIES ADDED TO THE NASDAQ BIOTECHNOLOGY INDEX

Taysha Gene Therapies | December 16, 2021

news image

Taysha Gene Therapies Inc. a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced that it has been added to the Nasdaq Biotechnology Index in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021. “ Read More

MEDICAL

MOGRIFY ANNOUNCES EXPLORATORY RESEARCH COLLABORATION WITH MRC LABORATORY OF MOLECULAR BIOLOGY

Mogrify | January 11, 2021

news image

Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstr...

Read More

CELL AND GENE THERAPY

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

news image

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More
news image

MEDTECH

GP-WRITE PARTNERS WITH DNA SCRIPT TO ACCELERATE DNA-WRITING TECHNOLOGY AND ACCESSIBILITY

Genome Project-write | October 18, 2021

GP-write’s CAD is a one-stop shop for microbe, plant and animal genome writing and redesign. Its automated workflow allows users to rapidly upload a genome, redesign it and synthesize the new sequence. The tool enables researchers to directly order synthetic DNA or related products and services from GP-write’s affiliated members. DNA Script’s SYNTAX System, a benchtop DNA printer powered by their groundbreaking enzymatic DNA synthesis (EDS) technology, enables us...

Read More
news image

CELL AND GENE THERAPY

TAYSHA GENE THERAPIES ADDED TO THE NASDAQ BIOTECHNOLOGY INDEX

Taysha Gene Therapies | December 16, 2021

Taysha Gene Therapies Inc. a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, announced that it has been added to the Nasdaq Biotechnology Index in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Monday, December 20, 2021. “ Read More

news image

MEDICAL

MOGRIFY ANNOUNCES EXPLORATORY RESEARCH COLLABORATION WITH MRC LABORATORY OF MOLECULAR BIOLOGY

Mogrify | January 11, 2021

Mogrify Limited (Mogrify®), a UK organization expecting to change the advancement of ex vivo cell therapies and pioneer the field of in vivo reconstructing treatments, and the MRC Laboratory of Molecular Biology (LMB), a top notch research lab committed to understanding significant natural cycles at the sub-atomic level, today reported an exploratory examination cooperation. The venture intends to create novel protein articulation frameworks by utilizing late advances in direct cell reconstr...

Read More
news image

CELL AND GENE THERAPY

NEUEXCELL THERAPEUTICS AND SPARK THERAPEUTICS ANNOUNCE RESEARCH COLLABORATION AGREEMENT TO DEVELOP A NOVEL GENE THERAPY FOR HUNTINGTON'S DISEASE

NeuExcell Therapeutics | September 13, 2021

NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering from Huntington's Disease (HD). Under the terms of the agreement, Spark Therapeutics will receive access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities. NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the prog...

Read More